Kymera Results Presentation Deck

At least 72h of Target Degradation Observed with Once Every Three-week Dosing Target Degradation in PBMC by FLOW Cycle 2 DL1 0.16mg/kg IRAK4 Percent Change from Baseline Ikaros Degradation Profile of IRAK4, Ikaros and Aiolos in DL1/DL2 Consistent with Preclinical Models in Blood and Tumor Aiolos Percent Change DL2 0.32mg/kg 100- 50- 0 -50- -100 0 -20- -40- -60- -80- -100 200 150 100 50 50. -50 -100 0 0 2 0 2 24 96 192 15 0 Hours Days Cycle 1 2 24 96 192 15 0 2 Hours Days 24 Hours 2 24 192 15 Hours Days 96 192 15 Days A 2 0 24 192 15 Hours Days 24 192 15 Hours Days KYMERA ©2022 KYMERA THERAPEUTICS, INC. ● Dose Level DL1 DL2 Dose Level DL1 DL2 Dose Level DL1 DL2 Cycle 1 -16% -27% Cycle 1 -84% -92% Cycle 1 -93% -100% Cycle 2 0 -40% Cycle 2 -88% -95% Cycle 2 - 91% -100% Up to 40% KD of IRAK4 and 95/100% KD of Ikaros and Aiolos in PBMC at DL1-2 Target Knockdown in Tumor by Targeted MS Percent Change from Baseline at C3D4 104-002: 0.16mg/kg Mean* SEM % Change 40 20 O -20 -40 -60 -80- -100 -41% -66% -27% Ikaros Aiolos IRAK4 *Mean is from 2-3 peptides measured for each analyte PAGE 21

View entire presentation